About BioRock Ventures
BioRock Ventures is a venture capital firm founded in 2019. It is primarily based out of San Francisco, United States. As of Oct 2020, BioRock Ventures has invested in 7 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and Healthcare. Most recently it participated in the $***** Series A round of Primmune Therapeutics Overall, BioRock Ventures portfolio has seen 2 IPOs, namely Vaxcyte and AN2 Therapeutics. A lot of funds co-invest with BioRock Ventures, with names like Mountain Group Partners sharing a substantial percentage of its portfolio. BioRock Ventures has team of 2 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed & Series A
Portfolio IPOs
BioRock Ventures' List of Top Investments
BioRock Ventures has a portfolio of 7 companies. Their most notable investmentis in Primmune TherapeuticsTheir portfolio spans across and United States. They have invested in Life Sciences, Enterprise Applications, Healthcare, across Seed, Series A stages. Here is the list of top investments by BioRock Ventures:
1. Vaxcyte
Developer of vaccines to treat infectious diseases. The company uses the cell-free protein synthesis platform called XpressCFTM along with the company's proprietary knowledge base to design and produce protein carriers and antigens for site-specific conjugation (building blocks of vaccines) for developing antigens and pneumococcal conjugate vaccines (VAS-24). It is also developing vaccines for invasive, pneumococcal diseases, otitis media, strep infections, and periodontitis.
Key facts about Vaxcyte
- Founded Year: 2013
- Location: Foster City (United States)
- Stage: Public
- Total Funding till date: $283M
- Employee Count: 109 as on Jul 01, 2024
- Investors: HTIF, Janus Henderson Investors and 15 Others
- Latest Funding Round: Series D, Apr 03, 2020, $*****
- Highlight: Public
Developer of drugs for treating infectious disease. The company is developing novel small molecule therapeutics, designing and executing clinical trials on experimental treatments, and navigating the regulatory approval process for new medicines.
Key facts about AN2 Therapeutics
- Founded Year: 2017
- Location: Menlo Park (United States)
- Stage: Public
- Total Funding till date: $92M
- Employee Count: 35 as on Feb 28, 2023
- Investors: BVF Partners, RA Capital Management and 10 Others
- Latest Funding Round: Series B, Jan 07, 2022, $*****
- Highlight: Public
Primmune Therapeutics is developing immunotherapies for treating cancer. They are developing a small molecule (orally administered) which is a toll-like receptor 7 (TLR7) agonist (an endosomal innate immune sensor capable of detecting single-stranded ribonucleic acid) helps in systemic activation of innate immunity. It gets expressed on plasmacytoid dendritic cells.
Key facts about Primmune Therapeutics
- Founded Year: 2017
- Location: San Diego (United States)
- Stage: Series A
- Total Funding till date: $51.4M
- Employee Count: 9 as on Jul 01, 2024
- Investors: CAM Capital, Oberland Capital and 8 Others
- Latest Funding Round: Series A, Nov 04, 2021, $*****
- Highlight: Editors' Pick
Octagon Therapeutics is developing small molecule based therapeutics against bacterial infections. The company has developed OTG005 which is an inhibitor of a rate-limiting enzyme and can be used for the treatment of diseases caused by antibiotic resistant Pseudomonas aeruginosa and Acinetobacter baumanii.
Key facts about Octagon Therapeutics
- Founded Year: 2017
- Location: Cambridge (United States)
- Stage: Series A
- Total Funding till date: $12.4M
- Investors: Slater Technology Fund, FLOBAS Ventures and 4 Others
- Latest Funding Round: Series A, Jan 29, 2024, $*****
Veana Therapeutics is developing alpha-tocopheryloxyacetic acid (Alpha-TEA, a vitamin E analog) cancer immunotherapy technologies. Alpha-TEAs are based on orally bioavailable anti-cancer agents that simultaneously kill tumor cells and stimulate the immune system. Its lead product Vimo 101 (a TEA – Lys) is in Phase 1 clinical trials and is being developed for melanoma, esophageal renal cell carcinoma, cecal carcinoma, thyroid cancer, prostate cancer, parapharygeal cancer, and oral squamous small cell lung cancer.
Key facts about Veana Therapeutics
- Founded Year: 2012
- Location: Portland (United States)
- Stage: Seed
- Total Funding till date: $10M
- Employee Count: 1 - 10 as on Jul 01, 2024
- Investors: BioRock Ventures, OTRADI and 1 Other
- Latest Funding Round: Grant (prize money), Aug 01, 2021, $*****
- Highlight: Editors' Pick
BioRock Ventures' Year-on-Year Investment Trends
Its most recent first time investment was in Primmune Therapeutics and most recent follow-on round was in Primmune Therapeutics.BioRock Ventures' Investments by Stage
BioRock Ventures has made 1 investment in Seed stage with an average round size of $7M and 1 investment in Series A stage with an average round size of $12M.BioRock Ventures' Investments by Sector
BioRock Ventures has a diverse portfolio, with companies operating in the Life Sciences and Sustainability Tech. Notably, it has invested in 6 Tech companies, 5 Enterprise (B2B) companies, 1 Consumer (B2C) company and at least 1 company focusing on Social impact.Sector | No. of Investments |
|---|---|
Life Sciences | 2 |
Sustainability Tech | 1 |
Note: We have considered here, only first round of investments
BioRock Ventures' Investments by Geography
BioRock Ventures has made most investments in United States (2).BioRock Ventures' recent investments
BioRock Ventures has not made any investment in 2026 so far.Here are the most recent investments by BioRock Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Oct 27, 2020 | United States | Series A | 7811 | [+5] | |
Mar 02, 2020 | United States | Seed | 2120 | [+2] | |
Nov 21, 2019 | United States | Series A | 6481 |
IPOs and Publicly Listed companies in BioRock Ventures' Portfolio
2 of BioRock Ventures' portfolio companies have become public. AN2 Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Mar 2022 at marketcap of $281M and Vaxcyte got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $774M.Here are BioRock Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 25, 2022 | Nov 21, 2019 | Series A | 3751 | |
Jun 12, 2020 | - | - | 7038 |
Team profile of BioRock Ventures
BioRock Ventures has a team of 2 members including 2 Partners located in United States. BioRock Ventures' team does not sit on the board of any company as of now.Co-investors of BioRock Ventures
Over the past 7 years, 17 investors have co-invested in BioRock Ventures's portfolio companies. This includes funds and angels.
- Top Co-investors of BioRock Ventures: 6 investors entered a company along with BioRock Ventures. These include investors like Mountain Group Partners (1 company).
- Invested after BioRock Ventures: A total of 11 investors have invested in BioRock Ventures's portfolio after their investments. Top Investors include RA Capital Management (1 company), BVF Partners (1 company) and Monashee Investment Management (1 company).
Recent News related to BioRock Ventures
•
Biotech startup Primmune Therapeutics nabs $7M seed funding to harness the power of immune system for the treatment of cancer and viral diseasesTechStartups.com•Mar 02, 2020•Primmune Therapeutics, CAM Capital, BioRock Ventures
•
AN2 Therapeutics Raises $12M in Series A FundingFinSMEs•Nov 21, 2019•AN2 Therapeutics, Mountain Group Partners, Adjuvant Capital, Brii Biosciences and 1 other
